
Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials
Glenn Yiu, MD, PhD, is a professor of ophthalmology at the University of California, Davis Eye Center in Sacramento, California. He is a consultant for 4DMT, AbbVie, Adverum Biotechnologies, Alcon, Bausch + Lomb, Boehringer Ingelheim, Clearside Biomedical, Endogena Therapeutics, Genentech, Iridex, Janssen Pharmaceuticals, jCyte, Myrobalan Therapeutics, NGM Biopharmaceuticals, Nanoscope, Novartis, Ocuphire, Opthea, Ray Therapeutics, Regenxbio, Samsung Bioepis, Stealth BioTherapeutics, Supra Medical, Surrozen, and West Pharmaceutical Services.